摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(2-羟乙基)环己醇 | 74058-21-2

中文名称
4-(2-羟乙基)环己醇
中文别名
4-(2-羟乙基)环己醇(顺反异构体混合物);4-(2-羟乙基)环己醇(顺反异构体混和物)
英文名称
4-(2-hydroxyethyl)cyclohexanol
英文别名
1-(4-Hydroxy-cyclohexyl)-aethanol-(2);β-(4-Hydroxycyclohexyl)-ethanol;(4-Hydroxy-cyclohexan)-aethanol;4-(2-hydroxyethyl)cyclohexan-1-ol
4-(2-羟乙基)环己醇化学式
CAS
74058-21-2
化学式
C8H16O2
mdl
MFCD11036247
分子量
144.214
InChiKey
SZIBVWWQOOVXHS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    175 °C / 20mmHg
  • 密度:
    1.05

计算性质

  • 辛醇/水分配系数(LogP):
    0.7
  • 重原子数:
    10
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    40.5
  • 氢给体数:
    2
  • 氢受体数:
    2

SDS

SDS:0dab017e0661887aecd49164634cca44
查看

Section I.Chemical Product and Company Identification
Chemical Name 4-(2-Hydroxyethyl)cyclohexanol (cis- and trans-
mixture)
Portland OR
Synonym Cyclohexaneethanol, 4-hydroxy- (CA INDEX NAME);
2-(4-Hydroxycyclohexyl)ethanol;
4-Hydroxycyclohexaneethanol
Chemical Formula C8H16O2
CAS Number 74058-21-2

Section II. Composition and Information on Ingredients
Toxicology Data
Chemical Name CAS Number Percent (%) TLV/PEL
4-(2-Hydroxyethyl)cyclohexanol (cis- and trans- mixture) 74058-21-2 Min. 98.0 (GC) Not available. Not available.

Section III. Hazards Identification
Acute Health Effects No specific information is available in our data base regarding the toxic effects of this material for humans. However,
exposure to any chemical should be kept to a minimum. Skin and eye contact may result in irritation. May be harmful if
inhaled or ingested. Always follow safe industrial hygiene practices and wear proper protective equipment when handling
this compound.
Follow safe industrial hygiene practices and always wear proper protective equipment when handling this compound.
Chronic Health Effects CARCINOGENIC EFFECTS : Not available.
MUTAGENIC EFFECTS : Not available.
TERATOGENIC EFFECTS : Not available.
DEVELOPMENTAL TOXICITY: Not available.
Repeated or prolonged exposure to this compound is not known to aggravate existing medical conditions.

Section IV. First Aid Measures
Check for and remove any contact lenses. In case of contact, immediately flush eyes with plenty of water for at least 15
Eye Contact
minutes. Get medical attention.
In case of contact, immediately flush skin with plenty of water. Remove contaminated clothing and shoes. Wash clothing
Skin Contact
before reuse. Thoroughly clean shoes before reuse. Get medical attention.
If the victim is not breathing, perform mouth-to-mouth resuscitation. Loosen tight clothing such as a collar, tie, belt or
Inhalation
waistband. If breathing is difficult, oxygen can be administered. Seek medical attention if respiration problems do not
improve.
Ingestion INDUCE VOMITING by sticking finger in throat. Lower the head so that the vomit will not reenter the mouth and throat.
Loosen tight clothing such as a collar, tie, belt or waistband. If the victim is not breathing, perform mouth-to-mouth
resuscitation. Examine the lips and mouth to ascertain whether the tissues are damaged, a possible indication that the toxic
material was ingested; the absence of such signs, however, is not conclusive.

Section V. Fire and Explosion Data
Not available.
May be combustible at high temperature. Auto-Ignition
Flammability
Flash Points Flammable Limits Not available.
Not available.
Combustion Products These products are toxic carbon oxides (CO, CO2).
Fire Hazards
Not available.
Risks of explosion of the product in presence of mechanical impact: Not available.
Explosion Hazards
Risks of explosion of the product in presence of static discharge: Not available.
Fire Fighting Media
SMALL FIRE: Use DRY chemical powder.
LARGE FIRE: Use water spray, fog or foam. DO NOT use water jet.
and Instructions
Consult with local fire authorities before attempting large scale fire-fighting operations.
Continued on Next Page
4-(2-Hydroxyethyl)cyclohexanol (cis- and trans- mixture) Page 2

Section VI. Accidental Release Measures
Spill Cleanup Absorb with an inert material and put the spilled material in an appropriate waste disposal. Finish cleaning the spill by rinsing
any contaminated surfaces with copious amounts of water. Consult federal, state, and/or local authorities for assistance on
Instructions
disposal.

Section VII. Handling and Storage
Handling and Storage Keep away from heat. Mechanical exhaust required. When not in use, tightly seal the container and store in a dry, cool
place. Avoid excessive heat and light. Do not breathe gas/fumes/ vapor/spray.
Information
Always store away from incompatible compounds such as oxidizing agents.

Section VIII. Exposure Controls/Personal Protection
Provide exhaust ventilation or other engineering controls to keep the airborne concentrations of vapors below their respective
Engineering Controls
threshold limit value. Ensure that eyewash station and safety shower is proximal to the work-station location.
Splash goggles. Lab coat. Vapor respirator. Boots. Gloves. Suggested protective clothing might not be sufficient; consult a
Personal Protection
specialist BEFORE handling this product. Be sure to use a MSHA/NIOSH approved respirator or equivalent.
Exposure Limits Not available.

Section IX. Physical and Chemical Properties
Liquid. (Clear, colorless ~ light yellow.) Solubility
Physical state @ 20°C Not available.
1.05 (water=1)
Specific Gravity
144.21
Molecular Weight Partition Coefficient Not available.
Boiling Point 175°C (347°F) @ 20 mmHg Vapor Pressure Not available.
Not available. Not available.
Melting Point Vapor Density
1.4900 - 1.4940 Volatility Not available.
Refractive Index
Not available.
Critical Temperature Not available. Odor
Viscosity Not available. Taste Not available.

Section X. Stability and Reactivity Data
Stability
This material is stable if stored under proper conditions. (See Section VII for instructions)
Conditions of Instability Avoid excessive heat and light.
Incompatibilities
Reactive with oxidizing agents.

Section XI. Toxicological Information
Not available.
RTECS Number
Routes of Exposure Eye Contact. Ingestion. Inhalation.
Not available.
Toxicity Data
Chronic Toxic Effects CARCINOGENIC EFFECTS : Not available.
MUTAGENIC EFFECTS : Not available.
TERATOGENIC EFFECTS : Not available.
DEVELOPMENTAL TOXICITY: Not available.
Repeated or prolonged exposure to this compound is not known to aggravate existing medical conditions.
No specific information is available in our data base regarding the toxic effects of this material for humans. However,
Acute Toxic Effects
exposure to any chemical should be kept to a minimum. Skin and eye contact may result in irritation. May be harmful if
inhaled or ingested. Always follow safe industrial hygiene practices and wear proper protective equipment when handling this
compound.
Follow safe industrial hygiene practices and always wear proper protective equipment when handling this compound.

Section XII. Ecological Information
Not available.
Ecotoxicity
Environmental Fate Not available.
Continued on Next Page
4-(2-Hydroxyethyl)cyclohexanol (cis- and trans- mixture) Page 3

Section XIII. Disposal Considerations
Waste Disposal Recycle to process, if possible. Consult your local regional authorities. You may be able to dissolve or mix material with a
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber system. Observe all
federal, state and local regulations when disposing of the substance.

Section XIV. Transport Information
Not a DOT controlled material (United States).
DOT Classification
PIN Number Not applicable.
Proper Shipping Name Not applicable.
Packing Group (PG) Not applicable.
DOT Pictograms

Section XV. Other Regulatory Information and Pictograms
TSCA Chemical Inventory This product is NOT on the EPA Toxic Substances Control Act (TSCA) inventory. The following notices are required by 40
CFR 720.36 (C) for those products not on the inventory list:
(EPA)
(i) These products are supplied solely for use in research and development by or under the supervision of a technically
qualified individual as defined in 40 CFR 720.0 et sec.
(ii) The health risks of these products have not been fully determined. Any information that is or becomes available will be
supplied on an MSDS sheet.
WHMIS Classification Not controlled under WHMIS (Canada).
(Canada)
EINECS Number (EEC) Not available.
EEC Risk Statements Not available.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-(2-羟乙基)环己醇溶剂黄146sodium hypochlorite 作用下, 以 为溶剂, 反应 1.33h, 以95%的产率得到4-(2-羟基乙基)环己酮
    参考文献:
    名称:
    WO2007/148208
    摘要:
    公开号:
  • 作为产物:
    描述:
    对羟基苯乙醇 在 palladium 10% on activated carbon Sodium tetraborate decahydrate 、 氢气 作用下, 以 异丙醇 为溶剂, 80.0 ℃ 、1.0 MPa 条件下, 反应 22.0h, 以99%的产率得到4-(2-羟乙基)环己醇
    参考文献:
    名称:
    WO2007/148208
    摘要:
    公开号:
点击查看最新优质反应信息

文献信息

  • Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
    申请人:Rodgers D. James
    公开号:US20070135461A1
    公开(公告)日:2007-06-14
    The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
    本发明提供了杂环取代的吡咯并[2,3-b]吡啶和杂环取代的吡咯并[2,3-b]嘧啶,可以调节雅努斯激酶的活性,并且在治疗与雅努斯激酶活性相关的疾病中具有用处,例如免疫相关疾病、皮肤疾病、髓增生性疾病、癌症和其他疾病。
  • POLYCARBONATE RESIN COMPOSITION AND FORMED PRODUCT THEREOF
    申请人:Monden Toshiki
    公开号:US20110245388A1
    公开(公告)日:2011-10-06
    In a polycarbonate resin composition containing a polycarbonate resin and a polycarbosilane compound, the use of the polycarbosilane compound modifies the surface properties of the polycarbonate resin composition without adversely affecting the intrinsic characteristics of the polycarbonate resin, such as transparency, heat resistance, and mechanical properties, e.g., impact resistance. A polycarbonate resin composition containing 100 parts by mass of a polycarbonate resin, 0.001 to 1 part by mass of a metal salt compound, and 0.005 to 5 parts by mass of a polycarbosilane compound has significantly improved flame resistance and high transparency and causes markedly reduced outgassing and mold fouling, without losing impact resistance and heat resistance.
    在含有聚碳酸酯树脂和聚碳硅烷化合物的聚碳酸酯树脂组合物中,使用聚碳硅烷化合物可以改变聚碳酸酯树脂组合物的表面特性,而不会对聚碳酸酯树脂的固有特性产生不利影响,如透明度、耐热性和机械性能(例如冲击强度)。含有100质量部聚碳酸酯树脂、0.001至1质量部金属盐化合物和0.005至5质量部聚碳硅烷化合物的聚碳酸酯树脂组合物具有显著提高的阻燃性和高透明度,显著减少气体排放和模具污染,同时不会损失冲击强度和耐热性。
  • <sup>16</sup> O/<sup>18</sup> O Exchange of Aldehydes and Ketones caused by H<sub>2</sub> <sup>18</sup> O in the Mechanistic Investigation of Organocatalyzed Michael, Mannich, and Aldol Reactions
    作者:Yujiro Hayashi、Takasuke Mukaiyama、Meryem Benohoud、Nishant R. Gupta、Tsuyoshi Ono、Shunsuke Toda
    DOI:10.1002/chem.201600280
    日期:2016.4.18
    reactions of aldehydes or ketones, as nucleophiles, have triggered several discussions regarding their reaction mechanism. H218O has been utilized to determine if the reaction proceeds through an enamine or enol mechanism by monitoring the ratio of 18O incorporated into the final product. In this communication, we describe the risk of H218O as an evaluation tool for this mechanistic investigation. We have
    醛或酮作为亲核试剂的有机催化迈克尔,曼尼奇和醛醇缩合反应引发了对其反应机理的若干讨论。H 2 18 O已用于通过监测掺入最终产物中的18 O的比例来确定反应是否通过烯胺或烯醇机理进行。在本交流中,我们将H 2 18 O的风险描述为该机理研究的评估工具。我们已经证明,由于H 2 18的存在,在醛或酮原料中发生16 O / 18 O交换在迈克尔,曼尼希和羟醛反应进行之前,先使用O和胺催化剂。由于新产生的18 O起始醛或酮和16 O水会影响最终产品中18 O的掺入比例,因此使用H 2 18 O不适用于区分这些有机催化反应的机理。
  • POLYHYDRIC PHENOL COMPOUND AND METHOD OF PRODUCING SAME
    申请人:MITSUBISHI CHEMICAL CORPORATION
    公开号:US20190210947A1
    公开(公告)日:2019-07-11
    The present invention provides a polyhydric phenol compound which has an excellent alkali resistance and which does not cause a deterioration in color even when used as a resin raw material or a color developer. The polyhydric phenol compound includes: a bisphenol compound (A) represented by the following Formula (1) and a trisphenol compound (B) represented by the following Formula (2): [wherein R 1 represents a monovalent aliphatic hydrocarbon group having from 6 to 24 carbon atoms; each of R 2 , R 3 , R 4 , R 5 and R 6 represents a monovalent hydrocarbon group having from 1 to 15 carbon atoms; and each of a, b, c, d and e represents an integer from 0 to 4]; wherein the trisphenol compound (B) is contained in an amount, in terms of absorption intensity ratio at 254 nm, of less than 1.6% by area with respect to the amount of the bisphenol compound (A).
    本发明提供了一种聚羟基酚化合物,具有优异的耐碱性能,并且即使用作树脂原料或颜料开发剂也不会导致颜色恶化。该聚羟基酚化合物包括:由以下公式(1)表示的双酚化合物(A)和由以下公式(2)表示的三酚化合物(B):[其中R1表示具有6至24个碳原子的单价脂肪烃基;R2、R3、R4、R5和R6中的每一个表示具有1至15个碳原子的单价烃基;a、b、c、d和e中的每一个表示0至4的整数];其中,以吸收强度比值(在254 nm处)计算,三酚化合物(B)的含量在面积上小于双酚化合物(A)的含量的1.6%。
  • [EN] APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES<br/>[FR] AGENTS INDUISANT L'APOPTOSE, DANS LE TRAITEMENT DU CANCER ET DE MALADIES IMMUNES ET AUTO-IMMUNES
    申请人:ABBOTT LAB
    公开号:WO2010138588A2
    公开(公告)日:2010-12-02
    Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
    本发明涉及一种抑制抗凋亡Bcl-2蛋白活性的化合物,包含该化合物的组合物以及治疗在其中表达抗凋亡Bcl-2蛋白的疾病的方法。
查看更多